Safety and Pharmacokinetics of Ciprofloxacin Dry Powder for Inhalation in Cystic Fibrosis: A Phase I, Randomized, Single-Dose, Dose-Escalation Study

Stass Heino; Delesen Heinz; Nagelschmitz Johannes; Staab Doris

首页> 外文期刊>Journal of aerosol medicine and pulmonary drug delivery >Safety and Pharmacokinetics of Ciprofloxacin Dry Powder for Inhalation in Cystic Fibrosis: A Phase I, Randomized, Single-Dose, Dose-Escalation Study

【24h】

Safety and Pharmacokinetics of Ciprofloxacin Dry Powder for Inhalation in Cystic Fibrosis: A Phase I, Randomized, Single-Dose, Dose-Escalation Study

机译：环丙沙星干粉在囊性纤维化中吸入的安全性和药代动力学：I期，随机，单剂量，剂量递增研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Reliable, reproducible deposition to the lung is a major prerequisite for the clinical use of inhaled drugs. Ciprofloxacin dry powder for inhalation (ciprofloxacin DPI; Bayer HealthCare AG, Leverkusen, Germany) is an antibacterial therapy in development using Novartis' PulmoSphere (TM) technology (Novartis Pharma AG, Basel, Switzerland) for the targeted delivery of ciprofloxacin to the lung via a T-326 inhaler.

机译：背景：可靠，可重复的肺部沉积是吸入药物临床使用的主要前提。环丙沙星干粉吸入剂（环丙沙星DPI;拜耳医药保健集团，德国勒沃库森）是一种使用诺华公司的PulmoSphere（TM）技术（诺瓦蒂斯制药公司，瑞士巴塞尔）开发的抗菌疗法，用于将环丙沙星经肺靶向递送一台T-326吸入器

著录项

来源
《Journal of aerosol medicine and pulmonary drug delivery》 |2015年第2期|共10页
作者
Stass Heino; Delesen Heinz; Nagelschmitz Johannes; Staab Doris;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
Ciprofloxacin DPI; Pseudomonas aeruginosa; Cystic fibrosis; lung targeting; long-term treatment;

机译：环丙沙星DPI;铜绿假单胞菌;囊性纤维化;肺靶向治疗;长期治疗;

相似文献

外文文献
中文文献
专利

1. Safety and Pharmacokinetics of Ciprofloxacin Dry Powder for Inhalation in Cystic Fibrosis: A Phase I, Randomized, Single-Dose, Dose-Escalation Study [J] . Stass Heino, Delesen Heinz, Nagelschmitz Johannes, Journal of aerosol medicine and pulmonary drug delivery . 2015,第2期

机译：环丙沙星干粉在囊性纤维化中吸入的安全性和药代动力学：I期，随机，单剂量，剂量递增研究
2. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis [J] . Aksamit Timothy, Bandel Tiemo-Joerg, Criollo Margarita, Contemporary clinical trials . 2017,第期

机译：呼吸试验：三相III，随机化，多期式，加元对照对照试验，用于吸入（环丙沙星DPI）在非囊性纤维化支气管扩张中的吸入（环丙沙星DPI）
3. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: A phase II randomised study [J] . WilsonR., WelteT., PolverinoE., The European respiratory journal : . 2013,第5期

机译：环丙沙星干粉用于非囊性纤维化支气管扩张的吸入：II期随机研究
4. Dry powder inhalable bacteriophage-polymeric particles reduce lung cystic fibrosis bacterial infections [C] . Rachit Aaarwal, Christopher Johnson, Barry Imhoff, Society for Biomaterials annual meeting and exposition . 2017

机译：干粉吸入性噬菌体多聚颗粒减少肺囊性纤维化细菌感染
5. Development of inhalable dry powder antibiotics and on-bead transcription strategies [D] . Manion, J'aime 2011

机译：吸入式干粉抗生素的开发和珠上转录策略
6. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study [O] . Robert Wilson, Tobias Welte, Eva Polverino, -1

机译：环丙沙星干粉用于非囊性纤维化支气管扩张的吸入：II期随机研究
7. Tolerability and Pharmacokinetic Properties of Ciprofloxacin Dry Powder for Inhalation in Patients With Cystic Fibrosis: A Phase I, Randomized, Dose-Escalation Study [O] . Stass Heino, Weimann Boris, Nagelschmitz Johannes, 2013

机译：环丙沙星干粉吸入性囊性纤维化患者的耐受性和药代动力学特性：第一阶段，剂量递增研究

Safety and Pharmacokinetics of Ciprofloxacin Dry Powder for Inhalation in Cystic Fibrosis: A Phase I, Randomized, Single-Dose, Dose-Escalation Study

摘要

著录项

相似文献

相关主题

期刊订阅